| 王宁,匡歆,赫宁宁.血清白细胞介素 -35、乳酸脱氢酶在骨髓增生异常综合征 120例中的临床意义[J].安徽医药,2024,28(1):105-110. |
| 血清白细胞介素 -35、乳酸脱氢酶在骨髓增生异常综合征 120例中的临床意义 |
| Clinical significance of serum interleukins-35 and lactate dehydrogenase in 120 cases with myelodysplastic syndrome |
| |
| DOI：10.3969/j.issn.1009-6469.2024.01.022 |
| 中文关键词: 骨髓增生异常综合征 治疗结果 白细胞介素 -35 乳酸脱氢酶 中性粒细胞 血红蛋白类 |
| 英文关键词: Myelodysplastic syndrome Treatment outcome Interleukin-35 Lactate dehydrogenase Neutrophil Hemoglobin |
| 基金项目: |
|
| 摘要点击次数: 226 |
| 全文下载次数: 87 |
| 中文摘要: |
| 目的分析血清白细胞介素( IL)-35、乳酸脱氢酶( LDH)在骨髓增生异常综合征(MDS)中的临床意义，为探究 MDS的潜在靶点提供参考依据。方法选取青岛市胶州中心医院 2019年 5月至 2020年 5月收治的 128例 MDS病人作为研究对象，所有病人均根据指南在医院接受个体化治疗，于治疗 6个月疗程时评估病人治疗效果，分为治疗失败组( n=28)和治疗有效组( n= 92)。于治疗前检测研究相关指标［白细胞( WBC)、血小板( PLT)、中性粒细胞绝对计数( ANC)、红细胞( RBC)、血红蛋白( Hb)、 IL-35、LDH］并统计病人临床资料，分析血清 IL-35、LDH与 MDS病人治疗效果的关系，并检验 IL-35、LDH联合预测 MDS病人治疗失败的最佳阈值。结果 128例 MDS病人随访期间共剔除 8例， 120例 MDS病人，治疗 6个疗程时，治疗失败占 23.33%(28/ 120)，治疗有效组占 76.67%(92/120)；治疗失败组 WHO分型预后积分系统(WPSS)评分、修订的国际预后积分系统( IRSS-R)均高于治疗有效组，较高危病人占比多于治疗有效组(P<0.05)；治疗失败组全血 ANC，血浆 Hb、PLT低于治疗有效组，血清 IL-35、 LDH表达量高于治疗有效组( P<0.05)。经 logistics回归分析显示， MDS病人治疗失败与全血 ANC，血浆 Hb、PLT低表达，血清 IL-35、LDH高表达有关( P<0.05)。绘制 ROC曲线图发现，血清 IL-35、LDH单独及联合预测 MDS病人治疗失败风险截断值分别为 129.70 ng/L、324.28 U/L。限制性立方样条分析显示，血清 IL-35、LDH与 MDS病人治疗失败风险呈线性剂量反应关系。结论血清 IL-35、LDH水平与 MDS病人治疗失败风险呈线性剂量反应关系，检测血清 IL-35、LDH有助于预测 MDS病人治疗失败风险。 |
| 英文摘要: |
| Objective To analyze the clinical significance of serum interleukin (IL)-35 and lactate dehydrogenase (LDH) in myelodys-plastic syndrome (MDS) and to provide a reference for exploring potential targets of MDS.Methods A total of 128 MDS patients treat-ed in Jiaozhou Central Hospital of Qingdao from May 2019 to May 2020 were selected as the research subjects. All patients received in-dividualized treatment in the hospital according to the guidelines, the therapeutic effect of the patients was evaluated at the 6-month course of treatment, and they were divided into the treatment-failure group(n=28)and the treatment-effective group(n=92). Before treat-ment, the relevant indexes [white blood cell (WBC), platelet (PLT), absolute neutrophil count (ANC), red blood cell (RBC), hemoglobin(Hb), IL-35 and LDH] were measured and the clinical data of the patients were counted. To analyze the relationship between serum IL35 and LDH and the therapeutic effect of MDS patients, and to test the optimal threshold for the combination of IL-35 and LDH in pre- dicting the therapeutic failure of MDS patients.Results A total of 8 of 128 MDS patients were excluded during the follow-up period,and in 120 MDS patients, treatment failure accounted for 23.33% (28/120) and treatment effectiveness accounted for 76.67% (92/120)at the time of 6 courses of treatment. The WHO staged prognostic scoring system (WPSS) score and the revised international prognosticscoring system (IRSS-R) were higher in the treatment failure group than in the treatment effective group, and the percentage of higher-risk patients was greater than that in the treatment effective group (P < 0.05). Whole blood ANC, plasma Hb and PLT were lower in thetreatment failure group than in the treatment effective group, and serum IL-35 and LDH expression were higher than in the treatment ef- fective group (P < 0.05). Logistics regression analysis showed that treatment failure in MDS patients was associated with whole bloodANC, low expression of plasma Hb and PLT, and high expression of serum IL-35 and LDH (P < 0.05). ROC curve plotting revealed that the cutoff values of serum IL-35 and LDH alone and combined in predicting the risk of treatment failure in MDS patients were 129.70ng/L and 324.28 U/L, respectively. Restricted cubic spline analysis showed that there was a linear dose-response relationship between serum IL-35 and LDH and the risk of treatment failure in patients with MDS.Conclusion Serum IL-35 and LDH levels show a linear dose-response relationship with the risk of treatment failure in MDS patients, and the detection of serum IL-35 and LDH can help pre- dict the risk of treatment failure in MDS patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
